NUMIF NUMINUS WELLNESS INC
- 0.057800
- +0.000350+0.61%
NUMINUS WELLNESS INC News
Earnings Call Summary | NUMINUS WELLNESS INC(NUMIF.US) Q2 2024 Earnings Conference
The following is a summary of the Numinus Wellness Inc. (NUMIF) Q2 2024 Earnings Call Transcript:Financial Performance:Numinus reported Q2 2024 revenue of $5 million, down from $5.9 million in the pre
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Psychedelics healthcare company Numinus Wellness (OTCQX:NUMIF) shared its unaudited, condensed and consolidated interim financial results for the three and six months ended February 29, 2024. Q2 showe
Numinus Wellness Shares Down on Canadian Operations Reorganization
By Adriano Marchese Numinus Wellness shares were sharply lower late Monday morning after the mental health care company said it will consider divesting its Canadian clinical operations to focus on it
Numinus Wellness Reports Q2 Results
Notable Earnings After Monday's Close
Numinus Wellness Q2 Earnings Preview
Press Release: Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results
Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results PR Newswire VANCOUVER, BC, April 12, 2024 Q2 Fiscal 2024 Highlights -- Cash position of $6.6 million as of February 29, 2024
Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
Two separate deals hit the wires on Tuesday. One is PharmAla Biotech's (OTC:MDXXF) with Numinus Wellness (OTC:NUMIF) for a group therapy model with MDMA, the other is Optimi Health's (OTCQX:OPTHF) wit
PharmAla Biotech Signs Sale Agreement With Numinus Wellness
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Providers at Utah's two largest healthcare systems may now treat patients with psilocybin and MDMA as part of a pilot program created by a proposal-turned-law that will take effect as early as May 1,
Numinus Wellness Submits Clinical Trial Application
Numinus Wellness Congratulates MindMed on Positive Results From Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
Mind Medicine Sends Psychedelic Stocks Higher After FDA Status for LSD Formulation
Oregon House Passes Bill to End Hard Drug Decriminalization
There are many factors in setting drug policy, which often center around the benefits or detriments to a society and its economy.
Numinus Wellness Inc. Closes $6 Million Bought Deal Public Offering
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Can Psychedelics Increase Sexual Interest And Satisfaction? Study Says Yes And Effects Can Last MonthsA new study suggests a potential link between the use of psychedelics like magic mushrooms and LSD
Press Release: Numinus Wellness Inc. Congratulates Lykos Therapeutics on FDA Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
Numinus Wellness Inc. Congratulates Lykos Therapeutics on FDA Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD Canada NewsWire VANCOUVER, BC, Feb. 14, 2024 Numinus Welcomes Psy
Psychedelic Stocks Gain After FDA Priority Review for MDMA Therapy
Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering With Leads Orders From MAPS and Integrated V.C.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia
Analysis
Price Target
No Data
